Site-Specific Chemoenzymatic Protein Modifications
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 61/883,050, filed Sep 26, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,084,781 | Mek Mutations Conferring Resistance to Mek Inhibitors In force · High confidence UsedRemaining | Dana-Farber Cancer Institute, Inc. | In force | High confidence | ||
| US 9,540,619 | MELK Regulation for the Treatment of Breast Cancer In force · High confidence | Novartis AG | In force | High confidence | ||
| US 9,359,400 | Site-Specific Chemoenzymatic Protein Modifications In force · High confidence | Novartis AG | In force | High confidence | ||
| US 10,975,120 | Site-Specific Chemoenzymatic Protein Modifications In force · High confidence | Novartis AG | In force | High confidence | ||
| US 9,540,324 | Selective Octahydro-Cyclopenta[c] Pyrrole Negative Modulators of NR2B In force · High confidence | Novartis AG | In force | High confidence | ||
| US 11,116,749 | Selective Octahydro-Cyclopenta[c]pyrrole Negative Modulators of NR2B In force · High confidence | Novartis AG | In force | High confidence | ||
| US 10,239,835 | N-ALKYLARYL-5-Oxyaryl-OCTAHYDRO-CYCLOPENTA[C]PYRROLE Negative Allosteric Modulators of NR2B In force · High confidence | Novartis AG | In force | High confidence | ||
| US 10,781,174 | N-ALKYLARYL-5-Oxyaryl-OCTAHYDRO-CYCLOPENTA[C]PYRROLE Negative Allosteric Modulators of NR2B In force · High confidence | A.O. International II, Inc. | In force | High confidence | ||
| US 12,145,909 | N-ALKYLARYL-5-Oxyaryl-OCTAHYDRO-CYCLOPENTA[C]PYRROLE Negative Allosteric Modulators of NR2B In force · High confidence | Novartis AG | In force | High confidence | ||
| US 12,161,624 | Selective Octahydro-Cyclopenta[c]pyrrole Negative Modulators of NR2B In force · Medium confidence | Novartis AG | In force | Medium confidence | ||
| 6 more records in this group · Pro | ||||||
10 of 16 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 16, including 1 expired.
8 of these are in force and held by Novartis AG.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.